Cite

HARVARD Citation

    Hecht, J. et al. (2015). A Phase I, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into liver tumors. Journal for immunotherapy of cancer. 3 (2), p. 1. [Online]. 
  
Back to record